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Introduction: Idiopathic pulmonary fibrosis (IPF) is a relentlessly progressive and usually 
fatal lung disease of unknown etiology for which no effective treatments currently exist. In 
the adults type I and II pneumocytes, forms Components of the alveolar epithelial cells. In 
this study, we investigated the effect of thalidomide on the alveolar epithelial cells (type I and 
II pneumocytes) in the lung fibrosis induced by bleomycin in mice. 
Materials and methods: In this research, 32 male adult C57BL/6 mice were randomly 
divided into 4 groups. Mice received in group Bleomycin, bleomycin sulfate, in group 
Bleomycin+Thalidomide, bleomycin besides thalidomide, in group Thalidomide, only 
thalidomide and in group carboxymethylcellulose, carboxymethylcellulose via 
intraperitoneum. At the end of experiment, mice lung samples were prepared and histological 
studies were performed on them. After the investigation of tissue slides, number of type I and 
II pneumocytes were calculated and results were analyzed by using one-way ANOVA. 
Results: Histological studies showed a significant decrease in the number of  type I 
pneumocytes and a significant increase in the number of type II pneumocytes in the 
Bleomycin group in comparison with the carboxymethylcellulose group (p<0.001). But 
number of these cells (type I and II pneumocyte) in the Bleomycin+Thalidomide group 
increased and decreased respectively compared to the Bleomycin group (p<0.001). 
Conclusion: The results of this study showed that Thalidomide decreases number of 
pneumocytes II and increases pneumocytes I and Thereby reduces pulmonary fibrosis in the 
mice.  
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Introduction 
Idiopathic pulmonary fibrosis (IPF) is a 
progressive and often lethal lung disorder. 
The histopathological features of IPF are 
usual interstitial pneumonia, which 
consists of honeycombing, patchy fibrosis, 
lung epithelial cell dysfunction, lung 
fibroblast activation and proliferation, 
fibroblastic foci and hyperplasia of type II 
pneumocytes, excessive collagen 
deposition and subsequent destruction of 
the normal lung architecture with loss of 
alveolar spaces (1,2). IPF begins with 
repeated injury to the lining of the alveoli, 
which type II alveolar epithelial cells 
(AEC II) undergo hyperplasia and become 
suppliers of fibrogenic cytokines that 
induce the proliferation and migration of 
lung fibroblasts and eventually leads to 
extensive remodeling of the distal airspace 
of lung, stiffening it and making breathing 
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difficult. The prognosis for IPF patients is 
poor and current therapies are ineffective 
in preventing or even delaying the onset of 
respiratory failure. Novel therapeutic 
approaches include molecular targeting of 
specific signaling pathways activated 
during fibrotic processes (3,4). 
Thalidomide, a derivative of glutamic acid, 
was synthesised originally as a sedative 
and an anti-emetic. Subsequently the drug 
was withdrawn because of its teratogenic 
effects (5). Thalidomide was found 
effective first in erythema nodusum 
leprosum lesions (6), and later in 
rheumatological diseases (7), Crohn's 
disease (8), tuberculosis (9), cutaneous 
sarcoidosis (10) and lung transplantation 
(11). In addition, the ability of thalidomide 
to inhibit angiogenesis has led to its use in 
malignancy, particularly multiple 
myeloma (12). Previous studies have 
shown that thalidomide can inhibit the 
production of inflammatory cytokines such 
as TNF-α, IL-12 from peripheral blood 
mononuclear cells (PBMCs) and alveolar 
macrophages (Ams) (13–16) and IL-6 and 
TGF-β from lung fibroblasts (17). 
However, the mechanisms underlying the 
effects of thalidomide in interstitial lung 
disease are still unclear. In this study, we 
investigated the effect of thalidomide on 
the alveolar epithelial cell in the lung 
fibrosis induced by bleomycin in mice by 
morphometric theqniq and have shown 
that  thalidomide has an antifibrotic effect 
in the lung fibrosis by Reduction in type II 
alveolar epithelial cells and increase in 
type I alveolar epithelial cells. 
Materials and methods 
Ethical approval: Thirty two male adult 
C57BL/6 mice were used in this study. 
The study was carried out in strict 
accordance to guidelines of the 1975 
Declaration of Helsinki. 
Model of pulmonary fibrosis: Male 
C57BL/6 mice were injected 
intraperitoneally with bleomycin sulfate (2 
mg/ mouse). 
Treatment groups: Thirty two healthy 
male C57BL/6 mice weighting 20-25 g on 
average at the age of 6-8 weeks were 
randomly assigned into bleomycin (Bleo), 
bleomycin plus thalidomide (Bleo + Thal), 
thalidomide (Thal) and 
carboxymethylcellulose (CMC) groups 
(n=8 per group). Pulmonary fibrosis 
models were established in groups Bleo 
and Bleo + Thal by the intraperitoneal 
injection of 2 mg/mouce bleomycin sulfate 
(Nippon Kayaku, Japan) dissolved in 0.1 
ml carboxymethylcellulose(CMC) (Sigma, 
USA) 0.5% in days 1, 8 and 15. Group 
Bleo + Thal received bleomycin as was 
mentioned for the Bleo group in addition 4 
mg thalidomide (Sigma, USA) dissolved 
in 0.1 ml CMC 0.5% via intraperitoneal 
injections five times a week for 4 weeks. 
Group Thal received 4 mg thalidomide 
dissolved in 0.1 ml CMC 0.5% via 
intraperitoneal injections five times a week 
for 4 weeks, and group CMC received 0.1 
ml CMC 0.5% via intraperitoneal 
injections five times a week for 4 weeks 
(17,18). When the experiment finished, the 
mice were killed by high doses of 
ketamine anesthetic.  Thorax was opened 
and lungs were removed, after being 
washed with PBS, the lungs were placed in 
formalin 10%. The tissues were 
dehydrated at different levels and were 
embedded in paraffin. 
H&E staining: After molding, transverse 
sections of 6 µm thickness were prepared. 
Haematoxylin and eosin staining agents 
were purchased from Sigma-Aldrich. The 
prepared sections were stained with 
haematoxylin and eosin following the 
manufacturer’s standard protocol for 
morphological analysis. The slides were 
then investigated under a light microscope . 
PAS staining: Periodic acid schiff (PAS) 
is a staining method used to detect 
polysaccharides such as glycogen, and 
mucosubstances such as glycoproteins, 
glycolipids and mucins in tissues. The 
number of type I and II pneumocyte in this 
staining was detectable and ratio of them 
was calculated. In this method, for each 
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group, 10 fields of 10 sections were 
examined with 40X magnification . 
Statistical analysis 
The results were analyzed in SPSS, 
version 20 were presented as the mean ± 
standard error. The groups were compared 
using one-way ANOVA. P<0.05 was 
considered to indicate a statistically 
significant difference. 
Results 
Pathological changes: Four weeks after 
bleomycin instillation, in the Bleo group, 
there was pathological changes including 
thickening of alveolar walls, infiltration of 
inflammatory cells into the interstitium, 
disorganization of the alveolar structure, 
impairment of alveolar septa, development
of cystic changes in alveoli, and increased 
amount of connective tissue (Figure 1A). 
The number of cuboidal type II 
pnoumocyte increased which project into 
the lumen often occupying a niche in the 
corner of the alveoli and was shown by 
PAS staining (Figure 2A). In the group 
Bleo + Thal that received thalidomide 
besides bleomycin, compared to the Bleo 
group, The severity of changes diminished 
such as relative reduction in the 
inflammatory reaction, decreased 
thickness of alveolar septa, better 
organization of the alveolar structure, and 
fewer changes consistent with alveolar 
impairment were observed (Figure 1B), 
The number of type II pnoumocytes 
decreased in the PAS staining (Figure 2B). 
In the Thal and CMC groups No 
pathological changes were observed in the 




Figure 1. Effect of thalidomide on bleomycin induced lung fibrosis in mouse lung tissue. male adult C57BL/6 
mice were injected ip with bleomycin in the Bleo group (A). Mice in the Bleo + Thal group (B) received 
thalidomide besides bleomycin and in the Thal (C) and CMC (D) groups received thalidomide and 
carboxymethylcellulose respectively. After 4 weeks histological changes of lung tissue samples were shown by 
H&E staining. 




Figure 2. Effect of thalidomide on the alveolar epithelial cells in the lung fibrosis induced by bleomycin in mice.  
male adult C57BL/6 mice were injected ip with bleomycin in the Bleo group (A). Mice in the Bleo + Thal group 
(B) received thalidomide besides bleomycin and in the Thal (C) and CMC (D) groups received thalidomide and 
carboxymethylcellulose respectively. After 4 weeks, PAS staining were done on the lung tissue samples and the 
the alveolar epithelial cells (I and II pneumocytes) were observed. red arrows indicates the type II pneumocytes 
and black arrows indicates the type I pneumocytes.     
 
Quantitative results: The quantitative 
results related to the alveolar epithelial 
cells (type I and II pnoumocyte) of the 
mice lung simples in different groups were 
obtained by morphometric method. This 
data analysed using SPSS and one-way 
ANOVA. The mean values of type I 
pnoumocyte in the Bleo, Bleo + Thal, Thal 
and CMC groups were 2.83 ± 1.18 , 3.18 ± 
0.98 , 12.5 ± 4.85 , 10 ±  1.18 respectively 
(Figure 3). The mean values of type II 
pnoumocyte in the Bleo, Bleo + Thal, Thal 
and CMC groups were 8.30 ± 2.5 , 4.37 ± 
1.36 , 3.30 ± 1.25 and 2 ± 2.56 
respectively (Figure 4). 
 
 
     Figure 3. Mean number of type 1 pneumocytes in different groups.    
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In this experiment mice recieved in the 
Bleo, Bleo+Thal, Thal and CMC groups 
bleomycin,  bleomycin plus Thalidomide,  
Thalidomide and carboxymethylcellulose 
respectively. At the end of experiment, 
PAS staining were done on the lung tissue 
samples and the mean number of type 1 
pneumocytes in Different groups was 
calculated by SPSS and one-way ANOVA.
 
 
           Figure 4.  Mean number of type 2 pneumocytes in different groups. 
 
The results indicate an increase in the type 
I pnoumocyte in the Bleo + Thal group in 
comparison with the Bleo group. 
Statistical analysis showed that the groups 
have significant difference with each other 
in the mean value of type I and II 
pnoumocyte (P<0.001). 
Discussion  
In the current study, the effect of 
thalidomide on the alveolar epithelial cells 
(type I and II pnoumocyte) in the lung 
fibrosis induced by bleomycin was 
investigated. We demonstrated the 
relationship between thalidomide and 
pulmonary fibrosis. IPF is a chronic, 
progressive, and usually lethal lung 
disorder of unknown etiology. Although 
the pathogenic mechanisms have not been 
elucidated, aberrantly activated alveolar 
epithelial cells, which produce a variety of 
mediators during the development of the 
disease, seem to play a key role (19-21). 
We treated mice with bleomycin by 
intraperitoneal administration instead of 
intratracheal administration, as usually 
carried out in many reports, because study 
the effect of the drug when added to the 
whole body as this administration 
resembled more clearly the use of the drug 
in human cancer therapy. Bleomycin is an 
effective chemotherapeutic agent which its 
repeated systemic or high dose 
administration often leads to lung injury 
and fibrosis (22). Bleomycin-induced 
pulmonary fibrosis in animal models is 
very applicable for studying the cellular 
and molecular mechanisms of interstitial 
lung fibrosis (23  .(  
 Here, we found that thalidomide could 
inhibit lung fibrosis by preventing the 
proliferation of type II pneumocyte and 
increasing the type I pneumocyte in the 
alveolar epithelial cells. Researchers have 
studied the anti-fibrotic effect of 
thalidomide and reported that thalidomide 
could relieve the symptoms and stop the 
progression of lung fibrosis in the human 
and animal samples. In the study Tabeta 
and his colleagues in 2007 showed that 
thalidomide has inhibitory effect on 
bleomycin-induced pulmonary fibrosis in 
mice (17). They showed that thalidomide 
have prevention effect on synthesis of 
collagen, TGF-β, IL-6, and VEGF which 
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these marker have an important role in the 
lung fibrosis. Zhao and his colleagues in 
the 2009 demonstrated that thalidomide 
could be effective in treatment of lung 
fibrosis via its inhibitory effect on 
hydroxyproline (HYP) and α-SMA protein 
(24). Maureen et al. (2012) demonstrated 
that oral thalidomide in patients with lung 
fibrosis can considerably alleviate the 
patients’ cough (25). In summary all of the 
study mentioned above including our 
experiments demonstrates that thalidomide 
has an antifibrotic effect in the lung 
fibrosis. However the molecular 
mechanism of thalidomide is largely 
unknown and more research needs to be 
done . 
Conclusion 
In summary, we demonstrated that 
bleomycin induse the lung fibrosis and 
thalidomide by decrease of type II 
pneumocyte caused the decrease of lung 
fibrosis . 
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